for Thank our XX. everyone two call developing you, kidney ischemic significant to symptoms. our stroke. to chronic for and business financial welcome these on for mainly being the we very doctors Yesterday update disease our Michelle. I'd quarter Currently, release treating focused are like and there acute unmet quarterly earnings and are That medical with options important DMXXX DiaMedica for diseases results a quarter. with limited patients press issued of a March needs. ended summary is very few
Officer, filed in We found both Kellen. which by XX-Q, of reports joined website Chief Form www.diamedica.com. on be today our Financial quarterly of I'm investor can at section the our our Scott also
label study patients levels primarily disease. at conducted dose with This performed sites an you in being bring being trial, which year, program disease. to-date In kidney three a Xb clinical So open we in evaluate U.S. chronic is Phase are pleased February began with chronic first, we in of to on DMXXX the this the to DMXXX of patients our up three for pharmacokinetics kidney is enrolling patients,
in for kidney DMXXX subcutaneous with study, or XX a single looking chronic and Just as dose, a reminder a severe is moderate subjects we're disease. being in administered
Our tolerability the safety and standard measurements. endpoints include
the changes this reiterate a days. the purpose And levels, days safety of level of there's to kidney restore near to compared dose function determine a will biomarkers kidney KLKX of also us understand pharmacodynamics Knowing full use KLKX in dose to or period scientific the which levels in is and levels disease advisors XX of I'm help And measured in patients addition, we population. schedule now we're to ahead the our over safe thus chronic required tolerability pharmacokinetics, tolerated and profile normal and healthy patient evaluating well study in is XX identify in very In in this - whether and pharmacokinetic difference slightly studies been of DMXXX to report pleased volunteers. any DMXXX to far, this our level are X that Phase our and has our as previous and DMXXX enrollment, for trials. planned with
expect report top results in We June XXXX. line of clinical
about for protein. talk let therapeutic for you briefly protein form a us me We chronic If potential to for chronic moment, disease. as patients. KLKX indulge of disease treatment DMXXX is function, for the a by most synthetic referred vital the of kidney physiological as recombinant, offer body's prostacyclin medias has are including benefits kidney DMXXX and two which producing [ph], critical kidney kidney the also systems, important the in and a the plays believe a kidneys both critical key KLKX the These regulators hormones. DMXXX nitric oxide normal Nitric vital role are prostacyclin integrity. and of are oxide, and health anti-inflammatory brain. to
of deficit upon in studies nitric of medicine. kidney we believe Several have bradykinin, KLKX. low development have oxide fact, chronic And disease. in enzymes severe kidney chronic clinical physiology oxide to important levels disease to In have people prostacyclin Nobel to of mechanism discoveries these that for the patients the low and nitric been moderate contribute with of moderate understanding our have that shown kidney levels of of and basis the Based disease severe of action also prizes chronic and KLKX, and the with progression both prostacyclin.
blood levels replenish beneficial for production and to increasing with together basal by physiological thus release where protect is therapy reduce and needed position for KLKX flow and nitric lowering flow work injury. generating chronic renal blood improve dilation, oxidative increasing to kidney and option inflammation, as the levels goal when and Our disease bradykinin kidneys stress, synergistically from treatment patients of of oxide also which DMXXX ultimately fibrosis a DMXXX to lowering to to both prostacyclin, renal damage and
for respect to product expect study, about website half the and chronic kidney planning our Phase kidney X our under under learn the we're CKD, to can with chronic You study continuing in the second this chronic kidney initiate for disease XXXX. With of more the disease. disease
Advisory group and us to near-term. through world have These will the studied our will what about including we assist advisors studied Board We the also kidney plan be us in patients in kidney disease treatment clinical be disease. to developments. important to CKD coming on guide will in as be and kidney disease. with We in causes causes for of Phase further be to the chronic the very potential remain excited study updates believe an class identifying We're Scientific excited chronic formalizing chronic to recognized for targeted for selecting be a X, we targeted weeks DMXXX announce the the
enroll in REMEDY Turning our we subjects stroke, trial. continue our to progress to
ischemic today. experience to to Phase a designed this called stroke. the TPA a is the an and plan subjects with recruiting also in an therapeutic stroke. ischemic within generally its with are hours new we significant hospitals. study up This XXX We XX% subjects hour study, option approximately after Current double-blinded, treatment a offer safety, the after a randomized Activase, As XX are tolerability stroke you window, and know acute enroll for where who currently could trade drug DMXXX treatment XX administered must placebo-controlled ischemic acute XX in limited or believe an assess is population name markers stroke up than of stroke. to treatment X clock at hours We to which acute subjects patient DMXXX be less option within treatments following first four have breaking have
outcomes XX to with evaluating DMXXX a days therapeutic the and XX measurements potential. study stroke. is DMXXX's at patient investigate stroke following Our We're using standard
ischemic for Tissue Although journal, we want the of was peer This our call, lays manuscript that at Therapeutic last in Neurological a of in covering stroke treatment titled, reviewed I Disorders. paper discussed remind out the this an Kallikrein rationale scientific medical the acute interested to in with patients published Advances everybody KLKX Human experienced good stroke. literature presents treatment as acute and whoever for benefit in for anyone ischemic using patients. It's additional mechanistic therapy how pharmaceutical DMXXX KLKX of role overview biochemical stroke the - has understanding very can kidney the a document a
run first our enough success DMXXX. consistently DMXXX pharmaceuticals of facet DMXXX of to with liter of in a completed liters reliably of XXX developments having of new now is in in XXX market. the the batches. we've our complete. for I generate drug and which XXX the commenced and DMXXX. runs cannot it demonstrates We're abilities development another is quarter high us completion XXX the risk significant reliably the now of a consistently XXXX overstate production meter of eventually our and produce of the producing manufacturing next ability meet quality to large batch and of of importance needs another very the to current multiple our Previously, efficiently the Turning important pleased and program liters, and XXX, to successful of batches reduces liter had further This XXX and technical product. rapidly XXX successfully quantities We produced in development
to Harry me present DiaMedica CKD conference DMXXX efforts chronic disease, new the Alcorn was chronic Last Chief medical exposure called kidney the development, Medical development, highlight scientific first was Summit DMXXX disease. our and now on which chronic Officer, therapeutic let investment for was Next, kidney to disease in invited presentation also DMXXX kidney kidney a broaden Boston. X for week, of CKD, held to at focused the entitled drug introduction This for communities. in our of was disease. Dr. His
recently at presentations. this quarter month. later a Of Investor presenting will hard our Biotech On BE institutional forward optimistic turn XXXX XXXX. on Scott change Day, their of the our to we what and Investor IPO and we're I we financials like look dedication all commitment first to I made the summary presented that Class call upcoming investor investors to XXth more With the many significant very the the we Conference at Institutional scientific the company. to work front We with Annual for to future and investor thank provide to our their holds. and Hallum Craig will upcoming to of would employee progress Together over for have
